SEC Form D filing

Vinci Pharmaceuticals, Inc., 2026-01-26

An SEC Form D private-offering notice from Avon By The Sea, NJ, a $25,348,339 filer-stated offering target in Biotech. Filed 2026-01-26. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Vinci Pharmaceuticals, Inc. site↗ Verified via SEC Form D

Specialty ophthalmic company developing EPIPLANT, a needle free drug delivery platform for retinal diseases including diabetic macular edema and intermediate age related macular degeneration.

Filed 2026-01-26Filed to raise $25,348,339First money in 2026-01-02Raised so far $20,218,331HQ (as filed) Avon By The Sea, NJSector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified vincipharmaceuticals.com↗Named in the filing 5 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source